CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Overview

The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

Full Title of Study: “A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 2019

Detailed Description

This Bridging Extension is to determine if intravenous CD101 is safe [Day 45- 52 for subjects with candidemia only, or Day 52- 59 for subjects with invasive candidiasis with or without candidemia] and effective [Day 14 (± 1 day)] in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

Interventions

  • Drug: CD101
    • Intravenous antifungal therapy
  • Drug: Caspofungin
    • Intravenous antifungal therapy
  • Drug: Fluconazole
    • oral antifungal therapy
  • Drug: intravenous placebo
    • normal saline
  • Drug: oral placebo
    • microcrystalline cellulose

Arms, Groups and Cohorts

  • Experimental: Group 1
    • Subjects in the CD101 IV treatment group 1 (Part A Only – up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed. Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down.
  • Active Comparator: Group 3
    • Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia). After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.
  • Experimental: Group 2
    • Subjects in the CD101 IV treatment group 2 (Part B Only – up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed. Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]
    • Time Frame: From first dose of study drug through Days 45-52 for subjects with candidemia only or Days 52-59 for subjects with IC, with or without candidemia.
    • Number of Subjects with Incidence of Treatment Emergent Adverse Events based on clinical chemistry, hematology and urine analysis laboratory test, vital sign, physical exams and ECG abnormalities.
  • Resolution of Systemic Signs Attributable to Candidemia and/or Invasive Candidiasis and Mycological Eradication [Overall Success]
    • Time Frame: Day 14 (± 1 day)
    • Number of subjects with mycological eradication and complete resolution of all systemic signs of candidemia and/or invasive candidiasis which were present at baseline

Secondary Measures

  • Mycological Eradication and Resolution of Systemic Signs
    • Time Frame: Day 5, and Follow-up (FU Days 45-52 for subjects with candidemia only or Days 52-59 for subjects with IC, with or without candidemia.
    • Evaluate overall success signs (mycological eradication and resolution of systemic signs attributable to candidemia and/or IC) in the mITT population.
  • Mycological Eradication
    • Time Frame: Day 5, Day 14 (±1 day), and FU (Days 45-52 for subjects with candidemia only or Days 52-59 for subjects with IC, with or without candidemia)
    • Evaluate mycological success (eradication) in the mITT population.
  • Clinical Cure
    • Time Frame: Day 14 (±1 day) and FU (Days 45-52 for subjects with candidemia only or Days 52-59 for subjects with IC, with or without candidemia).
    • Evaluate clinical cure as assessed by the Investigator in the mITT population. Subjects must meet all of the following requirements: Resolution of attributable systemic signs and symptoms of candidemia/IC that were present at baseline No new systemic signs or symptoms attributable to candidemia/IC No additional systemic antifungal therapy administered for candidemia/IC The subject is alive
  • Evaluate PK (Cmax)
    • Time Frame: Day 1, 10 minutes before end of infusion (EOI)
    • Evaluate maximum plasma concentration (Cmax) (Part A only)
  • Evaluate PK (Cmin)
    • Time Frame: Day 8, predose
    • Evaluate minimum plasma concentration (Cmin) (Part A only)
  • Evaluate PK (Cmin)
    • Time Frame: Day 15, predose
    • Evaluate minimum plasma concentration (Cmin) (Part A only)

Participating in This Clinical Trial

Inclusion Criteria

  • mycological diagnosis of candidemia and/or invasive candidiasis from a sample taken less than or equal to 96 hours before randomization (defined as: at least 1 blood culture positive for Candida or positive test for Candida from a sponsor approved rapid diagnostic test or positive gram stain for yeast or positive culture for Candida spp. from a specimen obtained from a normally sterile site) – willing to initiate or continue medical treatment to cure infections, including receipt of antibiotics and surgical procedures, if required. Patients receiving only medications and measures for comfort and not cure should not be enrolled. – female subjects of child bearing potential <2 years post menopausal must agree to one barrier method and one highly effective method of birth control or sexual abstinence. – male subjects must be vasectomized, abstain from sexual intercourse, or agree to use barrier contraception (condom with spermicide), and also agree not to donate sperm from first dose of CD101 (Day 1) until 90 days following last administration of study drug. – willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally acceptable representative must provide informed consent on their behalf. – presence of one or more systemic signs attributable to candidemia and/or invasive candidiasis Exclusion Criteria:

  • Any of the following forms of IC: 1. Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed) 2. Osteomyelitis 3. Endocarditis or myocarditis 4. Meningitis, endophthalmitis, or any central nervous system infection – neutropenia – alanine aminotransferase or aspartate aminotransferase levels >10 fold the upper limit of normal – severe hepatic impairment in subjects with a history of chronic cirrhosis – greater than 48 hours systemic antifungal treatment at approved doses to treat candidemia – pregnant females – lactating females who are nursing – known hypersensitivity to CD101, caspofungin, any echinocandin, or to any of their excipients – previous participation in this or any previous CD101 study – recent use of an investigational medicinal product within 28 days of first dose of study drug or presence of an investigational device at the time of screening – Principal Investigator considers the subject should not participate – presence of indwelling vascular catheter or device that cannot be removed and is likely to be the source of candidemia

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cidara Therapeutics Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Taylor Sandison, MD MPH, Study Director, Cidara Therapeutics

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.